Abstract
Epilepsy represents a complex spectrum disorder, with patients sharing seizures as a common symptom and manifesting a broad array of additional clinical phenotypes. To understand this disorder and treat individuals who live with epilepsy, it is important not only to identify pathogenic mechanisms underlying epilepsy but also to understand their relationships with other health-related factors. Benchmarks Area IV focuses on the impact of seizures and their treatment on quality of life, development, cognitive function, and other aspects and comorbidities that often affect individuals with epilepsy. Included in this review is a discussion on sudden unexpected death in epilepsy and other causes of mortality, a major area of research focus with still many unanswered questions. We also draw attention to special populations, such as individuals with nonepileptic seizures and pregnant women and their offspring. In this study, we review the progress made in these areas since the 2016 review of the Benchmarks Area IV and discuss challenges and opportunities for future study.
Original language | English (US) |
---|---|
Pages (from-to) | 31S-39S |
Journal | Epilepsy Currents |
Volume | 20 |
Issue number | 1_suppl |
DOIs | |
State | Published - Jan 1 2020 |
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research grant funding was received from NIH/NINDS R01NS101156 (D.T.) and NINDS R01-44351 (J.E.J.). E.A.F. has received research funding from NeuroPace as part of multisite research studies and has received honoraria from Nutricia for a webinar and for serving on their Scientific Advisory Board. D.T. has received a consulting fee from Eisai Pharmaceuticals Inc as a Scientific Advisor and sponsored travel support from Citizens United for Research in Epilepsy and from the Alzheimer’s Association. J.A.K. has received research funding support from Praxis Precision Medicines, Inc and Ovid Pharmaceuticals, technology royalties from Xenon Pharmaceuticals, Stoke Therapeutics, LifeSplice Pharm, Novartis, Encoded Genomics, GW Pharma, and Neurocycle, consulting fees from Encoded Genomics, and serves on the Scientific Advisory Board of the FamilieScn2A Foundation. M.R.A. receives salary support from HRSA MCH T73MC00036-19-05 The LEND Center of Pittsburgh and NINDS U10NS077272 Network of Excellence in Neuroscience Clinical Trials (University of Pittsburgh CRS). The opinions expressed in this publication are those of the author(s) and do not necessarily reflect the views of the NIH or the AES. The authors thank Dace Almane, MS, for providing assistance with preparing the manuscript. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research grant funding was received from NIH/NINDS R01NS101156 (D.T.) and NINDS R01-44351 (J.E.J.). E.A.F. has received research funding from NeuroPace as part of multisite research studies and has received honoraria from Nutricia for a webinar and for serving on their Scientific Advisory Board. D.T. has received a consulting fee from Eisai Pharmaceuticals Inc as a Scientific Advisor and sponsored travel support from Citizens United for Research in Epilepsy and from the Alzheimer’s Association. J.A.K. has received research funding support from Praxis Precision Medicines, Inc and Ovid Pharmaceuticals, technology royalties from Xenon Pharmaceuticals, Stoke Therapeutics, LifeSplice Pharm, Novartis, Encoded Genomics, GW Pharma, and Neurocycle, consulting fees from Encoded Genomics, and serves on the Scientific Advisory Board of the FamilieScn2A Foundation. M.R.A. receives salary support from HRSA MCH T73MC00036-19-05 The LEND Center of Pittsburgh and NINDS U10NS077272 Network of Excellence in Neuroscience Clinical Trials (University of Pittsburgh CRS).
Keywords
- NINDS benchmarks for epilepsy research
- PNES
- cognition
- comorbidities
- consequences of treatment
- epilepsy benchmarks
- mortality
- pregnancy
- psychogenic nonepileptic events
- sudden unexpected death in epilepsy
ASJC Scopus subject areas
- Clinical Neurology